Video
Expert Outlines Treatment Approaches for Investigative Treatment in Advanced Prostate Cancer
Notably, the investigative treatment avoids many of the severe adverse effects common in traditional therapies.
New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.
Researcher Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, outlined the study methods in a recent interview with Pharmacy Times. Morris said trial participants received 200 mCi every 6 weeks for 4 cycles, with an option to increase to 6 cycles for patients who were responding. He added that the majority of the patients received 6 cycles.
Morris also emphasized how different the adverse events (AEs) are compared to AEs with taxane-based chemotherapy. Treatment with 177Lu-PSMA-617 does not result in neuropathy, changes in taste, alopecia, or neutropenic fever, Morris said.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
